ROS1-positive lung cancer: treatment options, taletrectinib and resistance

Make sure the report identifies a ROS1 driver

ROS1-positive lung cancer usually involves a gene fusion or rearrangement. The finding is different from a nonspecific reference to ROS1 expression. A pathology or molecular team may use additional testing to confirm a result when the screening assay is uncertain.

Request the complete report, including the test method and any fusion information. If tissue was limited, ask whether the result is sufficient to select a medicine. The aim is to establish a reliable treatment match without repeating tests that already answer the question.

Sources and references: [1] [2]

Compare the medicines using your starting situation

ROS1-directed options include drugs such as crizotinib, entrectinib, repotrectinib and taletrectinib, with indications varying by jurisdiction. Activity in the brain, prior exposure to a ROS1 inhibitor and tolerability influence the choice. A patient starting treatment and a patient with resistance are different clinical groups.

Ask why the proposed medicine fits now and which alternative the team considered. This is also a chance to discuss other prescriptions, liver health, heart-rhythm concerns and the monitoring that will be needed while taking an oral targeted drug.

Sources and references: [1] [3]

What taletrectinib adds to the discussion

The FDA approved taletrectinib in June 2025 for adults with locally advanced or metastatic ROS1-positive NSCLC. Its supporting TRUST-I and TRUST-II studies included patients who had not received a ROS1 inhibitor and patients previously treated with one ROS1 inhibitor.

Those groups had different treatment histories, so their response results should be interpreted separately. The studies support discussion of taletrectinib in these settings; the prescribing team still needs to assess the individual patient's prior drugs and current disease. A US indication is useful evidence, while treatment in China requires the current Chinese prescribing information.

Sources and references: [3]

Ask how the brain will be monitored

The ability of a ROS1 medicine to control disease in the brain is an important treatment consideration. Baseline MRI and later imaging help the team judge that aspect of control. Symptoms and the size or location of metastases may require local treatment as well.

If radiation is being postponed while a systemic medicine is started, ask for the follow-up interval and the symptoms that should bring the appointment forward. New weakness, a seizure or rapidly worsening headache needs urgent assessment rather than waiting for a routine review.

Sources and references: [1]

Describe where and how the cancer is growing

Progression confined to one or a few sites can lead to a different discussion from widespread progression. A local treatment may be considered in selected patients, while others need a systemic change. Scans should be reviewed alongside symptoms and the earlier treatment response.

Repeat molecular testing may identify a resistance alteration relevant to another ROS1 inhibitor or a trial. If the result comes from blood and finds nothing useful, ask whether tissue testing would add information. A new drug should have a clear rationale beyond being more recently developed.

Sources and references: [1] [2]

Taletrectinib has specific monitoring needs

Taletrectinib prescribing information includes warnings about liver injury, lung inflammation, QT prolongation, high uric acid, muscle problems with creatine phosphokinase elevation and fractures, as well as fetal harm. Discuss the tests and symptom checks needed before and during treatment.

Report new breathing difficulty, fainting, severe muscle symptoms or signs of liver problems promptly. Follow the prescription's food and interaction instructions, and tell the team about all supplements and medicines. If a dose is missed or vomited, use the team's written directions rather than improvising an extra dose.

Sources and references: [3]

Keep later treatment options in view

Chemotherapy remains an option when a suitable ROS1-directed medicine is unavailable, intolerable or no longer effective. Trials may investigate newer inhibitors or resistance approaches. The most relevant study is one whose entry criteria match your previous drugs and molecular findings.

If the cancer is progressing quickly, ask how long screening can reasonably take. A trial inquiry should fit around the medical urgency. Keep a record of why each previous treatment ended, since intolerance and resistance can lead to different next choices.

Sources and references: [1] [4]

Prepare a ROS1-focused appointment inquiry

For a Shanghai review, send the original ROS1 result, recent body and brain imaging, and a dated list of prior inhibitors. EastMedGo can help organize these records and clarify the appointment process using the lung cancer resources.

State whether the question is first-line selection, a side effect or progression after a named medicine. We can help ask the receiving hospital about required tests, local prescribing arrangements and coordination costs. This gives you a practical basis for deciding whether a visit would address the question you need answered.

Common questions